Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients

다국어 초록 (Multilingual Abstract)

Background: We estimated the prevalence and clinical impact of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA). The concordance between macromethod and glycopeptide resistance detection (GRD) E tests was determined. In addition, predictors of clinical outcomes in hospitalized patients with S. aureus bacteremia (SAB) or pneumonia (SAP) were evaluated.
Methods: We obtained 229 consecutive S. aureus isolates from all hospitalized patients at two university hospitals located in Busan and Yangsan, Korea. Standard, macromethod, and GRD E tests were performed. Additionally, we reviewed the medical records of all patients. Among the 229 patients, predictors of clinical outcomes were analyzed for 107 patients with SAB and 39 with SAP.
Results: Among the 229 isolates, 34.5% of S. aureus isolates and 50.7% of methicillin-resistant S. aureus isolates exhibited the hVISA phenotype based on the macromethod E test. hVISA was nearly associated with treatment failure in patients with SAB (P=0.054) and was significantly associated with treatment failure in patients with SAP (P=0.014). However, hVISA was not associated with 30-day mortality in patients with SAB or SAP. The concordance between the macromethod and GRD E tests was 84.2%.
Conclusions: hVISA is quite common in the southeastern part of Korea. hVISA is associated with treatment failure in patients with SAP.

참고문헌 (Reference)

1 Hiramatsu K, "Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance" 1 : 147-155, 2001

2 Kim MN, "Vancomycin-intermediate Staphylococcus aureus in Korea" 38 : 3879-3881, 2000

3 Musta AC, "Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years" 47 : 1640-1644, 2009

4 Howden BP, "Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility" 38 : 521-528, 2004

5 Appelbaum PC, "The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus" 12 (12): S16-S23, 2006

6 Sieradzki K, "The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection" 340 : 517-523, 1999

7 van Hal SJ, "Systemic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates" 55 : 405-410, 2011

8 Liu C, "Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods" 47 : 3040-3045, 2003

9 Mylotte JM, "Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort" 31 : 1170-1174, 2000

10 Guilarde AO, "Staphylococcus aureus bacteraemia: incidence, risk factors and predictors for death in a Brazilian teaching hospital" 63 : 330-336, 2006

11 Howden BP, "Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications" 23 : 99-139, 2010

12 Horne KC, "Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA" 53 : 3447-3452, 2009

13 Maor Y, "Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center" 45 : 1511-1514, 2007

14 Kumar M, "Persistent pneumonia: Underlying cause and outcome" 76 : 1223-1226, 2009

15 CLSI, "Performance standards for antimicrobial susceptibility testing. Twenty-fifth Informational supplement"

16 Lew DP, "Osteomyelitis" 364 : 369-379, 2004

17 Durack DT, "New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service" 96 : 200-209, 1994

18 Hiramatsu K, "Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility" 40 : 135-136, 1997

19 Klevens RM, "Invasive methicillin-resistant Staphylococcus aureus infections in the United States" 298 : 1763-1771, 2007

20 Kullar R, "Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets" 52 : 975-981, 2011

21 Neoh HM, "Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections" 6 : 13-, 2007

22 Harbarth S, "Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus" 158 : 182-189, 1998

23 Bae IG, "Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance" 200 : 1355-1366, 2009

24 Leonard SN, "Evaluation of the E test GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides" 63 : 489-492, 2009

25 Yusof A, "Evaluation of a new E test vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA" 46 : 3042-3047, 2008

26 Smith TL, "Emergence of vancomycin resistance in Staphylococcus aureus" 340 : 493-501, 1999

27 Song JH, "Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin" 48 : 4926-4928, 2004

28 Hiramatsu K, "Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin" 350 : 1670-1673, 1997

29 Park KH, "Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteremia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aurues" 67 : 1843-1849, 2012

30 Satola SW, "Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method" 49 : 177-183, 2011

31 Kim MN, "Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea" 40 : 1376-1380, 2002

32 Charles PG, "Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus" 38 : 448-451, 2004

33 Fong RK, "Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore" 28 : 983-987, 2009

34 Rybak MJ, "Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007)" 46 : 2950-2954, 2008

35 Cui L, "Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus" 41 : 5-14, 2003

36 Horan TC, "CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections" 13 : 606-608, 1992

37 González C, "Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms" 29 : 1171-1177, 1999

38 Sieradzki K, "Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus" 185 : 7103-7110, 2003

39 Wootton M, "A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital" 47 : 399-403, 2001

40 Levy MM, "2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference" 31 : 1250-1256, 2003